H. Lundbeck A/S (HLUYY)

[farviewhill]

Lunbeck, a Danish company, has been successfully engaged in drug research for many years, not only in it'sown country, but with a total of over 5000 individuals in partnerships with biotechs/pharmas all over the world.
Most recently they were a prime player in the development and marketing of the blockbuster drug, Lexapro, among others.

What especially interests me and it's commercial value is staggering if the drug comes to market, is a drug in phase III testing that extends the 3- hour window for a heart attack patient to get to the hospital for treatment to avoid catastrophic damage, to a 9 hour window. Yes NINE hours.
This, if the tests continue as they have to date, will revolutionize the treatment of cardiac event victims.

HLUYY can be bought like any stock, no special commissions, etc., and, imo, one's portfolio of truly established and continually promising drug companies, should include HLUYY.